Strategy

Neotropix is a clinical stage company focused on the discovery and development of potent and selective naturally occurring oncolytic virus therapies for well-defined cancer indications. The company’s proprietary oncolytic virus screening technology has enabled the identification of NTX-010 as the lead clinical program, and has yielded a pipeline of additional research leads for a variety of different cancers. Neotropix intends to enter into both discovery and product alliances with partners motivated to introduce first-in-class therapies for the treatment of cancer.

To learn more about Neotropix, click here.

Product Alliances

With NTX-010 approaching clinical proof-of-concept, Neotropix is interested in working with partners to assist in the development and commercialization of the product in worldwide markets. It is anticipated that NTX-010 would be ideally suited for Pharma, Vaccine, or Biotech companies with:

• A strategic interest in breakthrough oncology therapies, and established biologics product manufacturing capabilities; or

• A strategic interest in breakthrough oncology therapies, and a willingness to have product manufacturing occur via a third party relationship.

For further information about NTX-010, click here.

Discovery Partnerships

Neotropix has created a proprietary technology platform which is focused on the discovery of an expanding pipeline of highly targeted, naturally occurring oncolytic virus agents for the effective treatment of defined cancers. The company is actively engaged in the collection, screening, and characterization of oncolytic viruses from all over the world, and has demonstrated the capability to rapidly advance selected oncolytic agents into human clinical trials. Neotropix is interested in discussing discovery collaborations with companies seeking to create or expand a strategic oncology franchise with breakthrough products.

Start a Conversation with Neotropix

For further information and inquires about partnering with Neotropix, please contact Peter Lanciano (Tel: +1 617-460-1200; planciano@neotropix.com).